Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Samsung Medical Center |
---|---|
Information provided by: | Samsung Medical Center |
ClinicalTrials.gov Identifier: | NCT00323830 |
The objective of the trial is to compare disease-free survival between adjuvant capecitabine/cisplatin alone vs capecitabine/cisplatin with radiotherapy (chemoradiation) in curatively resected gastric cancer patients.
Condition | Intervention | Phase |
---|---|---|
Gastric Cancer Surgery |
Drug: Xeloda/Cisplatin +/- radiotherapy |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Phase III Randomized Controlled Trial of Adjuvant Capecitabine/Cisplatin Chemotherapy and Chemoradiation Therapy for Gastric Adenocarcinoma |
Estimated Enrollment: | 490 |
Study Start Date: | October 2004 |
Estimated Study Completion Date: | March 2006 |
Although gastrectomy is the only potentially curative treatment in gastric cancer patients, the overall survival results remain unsatisfactory. The main factor accounting for high mortality rate is the relapse after surgical resection. During the past few decades, the principle of combined modality treatment has been developed and applied in practice for various solid tumors and gastric cancer has not been an exception. In an attempt to prevent recurrence and increase the cure rate of gastric cancer patients after surgery, multiple studies using variable modalities have been undertaken. One of the landmark study in adjuvant trials was the Intergroup study INT-0116, which reported a significant improvement in survival with the use of chemoradiation therapy after gastric resection of stage Ib to IV gastric cancers. Thereafter, the chemoradiation therapy has gained popularity and has been increasingly recognized as a standard of care in U.S. Nevertheless, the result from INT-0116 study has been challenged by the fact that the surgical treatment applied in the trial was gastrectomy with limited lymph node dissection (D0 or D1) in 90% of cases. Therefore, it is debatable whether adjuvant chemoradiation therapy can confer survival benefit in patients with extensive lymph node dissection.
It is still disputable if chemoradiotherapy after D2 can improve the results of D2 alone. Thus, the assessment of the effect of adjuvant chemoradiotherapy in D2 resected gastric cancer is essential.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: So Youn Jung, RN | 822-3410-2985 | soyoun95.jung@samsung.com |
Korea, Republic of | |
Samsung Medical Center | Recruiting |
Seoul, Korea, Republic of |
Principal Investigator: | Won Ki Kang, MD | Samsung Medical Center |
Study ID Numbers: | SMC IRB 2004-08-10 |
Study First Received: | May 8, 2006 |
Last Updated: | May 8, 2006 |
ClinicalTrials.gov Identifier: | NCT00323830 |
Health Authority: | Korea: Food and Drug Administration |
gastric cancer radiotherapy postoperative therapy chemotherapy |
Capecitabine Stomach Diseases Digestive System Diseases Digestive System Neoplasms Cisplatin Gastrointestinal Diseases |
Stomach Neoplasms Gastrointestinal Neoplasms Stomach cancer Adenocarcinoma Neoplasms, Glandular and Epithelial Carcinoma |
Neoplasms Neoplasms by Site Neoplasms by Histologic Type Radiation-Sensitizing Agents |
Antineoplastic Agents Therapeutic Uses Physiological Effects of Drugs Pharmacologic Actions |